Log In
Print
BCIQ
Print
Print this Print this
 

CTL019 (formerly CART-19)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionAutologous T cells loaded with a lentiviral vector expressing CART-19, which consists of a cancer antigen-binding domain targeting CD19 linked to CD3-zeta/CD137 immunostimulatory domains
Molecular Target CD19
Mechanism of ActionGene therapy
Latest Stage of DevelopmentPhase I/II
IndicationAcute lymphoblastic leukemia (ALL)
Partner

University of Pennsylvania
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today